1] Kroeger PT Jr, Drapkin R. Pathogenesis and heterogeneity of ovarian cancer[J]. Curr Opin Obstet Gynecol, 2017, 29(1): 26-34.
[2] Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[3] Deb B, Uddin A, Chakraborty S. miRNAs and ovarian cancer: an overview[J]. J Cell Physiol, 2018, 233(5): 3846-3854.
[4] Zhang X, Zhou J, Xue D, et al. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer[J]. Int J Biol Macromol, 2019, 129(1): 227-232.
[5] Qiao K, Ning S, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 418.
[6] Nicolosi PA, Dallatomasina A, Perris R. Theranostic impact of NG2/CSPG4 proteoglycan in cancer[J]. Theranostics, 2015, 5(5): 530-544.
[7] Ye MH. CSPG4 promotes the proliferation and migration of epithelial ovarian cancer cells through c-Met and ERK1/2[D]. Hu’nan Hengyang: Nanhua University, 2018. (in Chinese)
叶迈豪. CSPG4通过c-Met和ERK1/2促进上皮性卵巢癌细胞增殖与迁移的研究[D]. 湖南衡阳:南华大学, 2018.
[8] Suzuki HI, Katsura A, Matsuyama H, et al. MicroRNA regulons in tumor microenvironment[J]. Oncogene, 2015, 34(24): 3085-3094.
[9] Gilam A, Edry L, Mamluk-Morag E, et al. Involvement of IGF-1R regulation by miR-515-5p modifies breast cancer risk among BRCA1 carriers[J]. Breast Cancer Res Treat, 2013, 138(3): 753-760.
[10] Pardo OE, Castellano L, Munro CE, et al. miR-515-5p controls cancer cell migration through MARK4 regulation[J]. EMBO Rep, 2016, 17(4): 570-584.
[11] Pinho FG, Frampton AE, Nunes J, et al. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation[J]. Cancer Res, 2013, 73(19): 5936-5948.
[12] Zhang H, Wang X, Huang H, et al. Hsa_circ_0067997 promotes the progression of gastric cancer by inhibition of miR-515-5p and activation of X chromosome-linked inhibitor of apoptosis (XIAP)[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 308-318.
[13] Li J, Tang Z, Wang H, et al. CXCL6 promotes non-small cell lung cancer cell survival and metastasis via down-regulation of miR-515-5p[J]. Biomed Pharmacother, 2018, 97(1): 1182-1188.
[14] Nicolosi PA, Dallatomasina A, Perris R. Theranostic impact of NG2/CSPG4 proteoglycan in cancer[J]. Theranostics, 2015, 5(5): 530-544.
[15] Winship A, Van Sinderen M, Heffernan-Marks A, et al. Chondroitin sulfate proteoglycan protein is stimulated by interleukin 11 and promotes endometrial epithelial cancer cell proliferation and migration[J]. Int J Oncol, 2017, 50(3): 798-804.
[16] Kang J, Li ZY, Chen L, et al. Research progress of CSPG4/NG2 in immunosuppressive therapy of glioma[J]. Chinese Journal of Minimally Invasive Neurosurgery, 2017, 22(1): 46-48. (in Chinese)
康剑, 李宗阳, 陈垒, 等. CSPG4/NG2在胶质瘤免疫抑制治疗中的研究进展[J]. 中国微侵袭神经外科杂志, 2017, 22(1): 46-48.
[17] Chen Y. Expression of CSPG4 in epithelial ovarian cancer and its clinical significance[D]. Hu’nan Hengyang: Nanhua University, 2018. (in Chinese)
陈嫣. CSPG4在上皮性卵巢癌组织中的表达及其临床意义[D]. 湖南衡阳:南华大学, 2018.
[18] Sun J. Expression of CSPG4 in pancreatic cancer and its correlation with prognosis[D]. Chongqing: Third Military Medical University, 2015. (in Chinese)
孙靖. CSPG4在胰腺癌中的表达及其与预后相关性的研究[D]. 重庆:第三军医大学, 2015.
|